This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

This study has been completed.
Odense University Hospital
Information provided by:
Vejle Hospital Identifier:
First received: February 15, 2007
Last updated: July 7, 2009
Last verified: July 2009
The primary objective of the the study is to investigate the changes in bone remodeling during Velcade treatment.

Condition Intervention Phase
Multiple Myeloma Drug: bortezomib Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

Resource links provided by NLM:

Further study details as provided by Vejle Hospital:

Primary Outcome Measures:
  • Changes in bone markers during treatment

Secondary Outcome Measures:
  • Changes in osteolysis during treatment

Estimated Enrollment: 20
Study Start Date: February 2007
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Detailed Description:

20 patients will be included in the study over a 2 year period. Before, during and after treatment we will measure NTX-I, CTX-I, CTX-MMP, bALP, DKK-1, PINP, TRAcP and PTH. NTX, CTX and CTX-MMP are measured to estimate bone degradation. TRAcP is measured to estimate the activity of the osteoclasts. bALP and DKK-1 is measured to evaluate the activity of the osteoblasts and PINP is measured as a marker of new bone formation. PTH is measured in order to evaluate if the positive effects that is observed in bone formation in relations to velcade treatment is due to the pulsative way velcade is administered.

The effect of the velcade treatment will be evaluated by x-ray, bone marrow and m-component.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previously untreated multiple myeloma

Exclusion Criteria:

  • Use of bisfosfonates
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00436059

University Hospital Odense
Odense, Denmark, 5000
Vejle Hospital
Vejle, Denmark, 7100
Sponsors and Collaborators
Vejle Hospital
Odense University Hospital
Principal Investigator: Torben Plesner, MD Vejle Hospital
  More Information Identifier: NCT00436059     History of Changes
Other Study ID Numbers: 2006/175
Study First Received: February 15, 2007
Last Updated: July 7, 2009

Additional relevant MeSH terms:
Multiple Myeloma
Bone Marrow Neoplasms
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Hematologic Neoplasms
Neoplasms by Site
Bone Marrow Diseases
Antineoplastic Agents processed this record on August 17, 2017